Skip to main content
QIANJIANG YONGAN PHARMACEUTICAL CO.,LTD. logo

QIANJIANG YONGAN PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 002365 ISIN · CNE100000LZ9 LEI · 655600AWPJRUVVFJIU42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002365

About QIANJIANG YONGAN PHARMACEUTICAL CO.,LTD.

https://www.chinataurine.com

QIANJIANG YONGAN PHARMACEUTICAL CO.,LTD. specializes in the large-scale production and global distribution of taurine. The company maintains a vertically integrated supply chain, producing ethylene oxide as a key precursor for its taurine manufacturing processes. Its product range encompasses pharmaceutical, food, and feed-grade taurine, supporting applications in functional beverages, infant nutrition, animal health, and medicinal products. Additionally, the company develops and markets a variety of health supplements and nutritional formulations. By leveraging advanced synthesis technologies and significant production capacity, it provides essential ingredients to the global food, beverage, and healthcare markets, emphasizing quality control and supply chain reliability.

Recent filings

Filing Released Lang Actions
关于完成经营范围变更登记并换发营业执照的公告
Regulatory Filings Classification · 75% confidence The document is a short corporate announcement about completion of business scope change registration and issuance of a new business license. It contains no financial statements or substantive financial data, nor is it a proxy, dividend notice, or capital change. It is a general regulatory disclosure falling under miscellaneous regulatory announcements.
2026-05-29 Chinese
上海市锦天城（武汉）律师事务所关于潜江永安药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter by a law firm regarding the convening, procedures, and validity of the 2025 annual shareholders’ meeting, verifying legality under Company Law and listing rules. It is not the AGM minutes or voting results announcement itself, nor is it a full annual report, earnings release, or financial supplement. It is an attestation/legal opinion, fitting the officer certification category, which under our rules should be classified as a general regulatory filing (RNS) rather than the underlying report type.
2026-05-27 Chinese
关于购买理财产品的进展公告
Regulatory Filings Classification · 88% confidence The document is a corporate announcement detailing the progress of using idle funds to purchase wealth management products (理财产品) under board authorization. It is not an annual or interim financial report, earnings release, governance change, dividend notice, share issuance, or debt financing. It serves as a general regulatory disclosure of a non-routine transaction and risk controls, fitting the fallback “Regulatory Filings” category.
2026-05-12 Chinese
2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '潜江永安药业股份有限公司2025年年度报告摘要' (Qianjiang Yongan Pharmaceutical Co., Ltd. 2025 Annual Report Summary). It contains key financial data, business descriptions, shareholder information, and management discussions for the fiscal year 2025. Although it is a 'summary' (摘要), it is a standard component of the official annual reporting process in the Chinese market (A-share listed companies), providing substantive financial and operational information. It is not a mere announcement of a report, but the report summary itself, which is classified under the 10-K category in this schema. FY 2025
2026-04-16 Chinese
关于“质量回报双提升”行动方案的公告
Regulatory Filings Classification · 65% confidence The document is an official announcement by a Shenzhen-listed company describing its “Quality Return Double Improvement” special action plan including strategies on operations, innovation, governance and disclosure quality. It is not a financial report (not an Annual Report, Interim Report, Earnings Release), nor shareholder vote results, nor a proxy statement, dividend notice, capital change, management change, legal proceeding, or any other specified category. It is a general regulatory announcement required by the exchange. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-04-16 Chinese
独立董事2025年度述职报告（赵纯祥）
Governance Information Classification · 82% confidence The document is a formal annual duty report (“述职报告”) by an independent director, detailing board attendance, committee activities, governance processes, and oversight measures. It does not announce board changes (MANG), issue financial results (10-K, IR, ER), or propose shareholder votes (PSI). It focuses on governance practices and the independent director’s performance within the board structure, matching the Governance Information (CGR) category.
2026-04-16 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.